By Harsha K Rajasimha – AI is heralding a new era in drug development, promising groundbreaking solutions to longstanding challenges. Traditional clinical trials are often plagued by manual processes, leading to prolonged timelines and soaring costs.
Read More
By Hiren Thakkar – Inadequate ethnic diversity in clinical trials, tight eligibility criteria, delayed or missing prescription recommendations for certain communities, and access gaps affecting global health are all hot topics in academia, business, and government.
By Emily Newton – Like many other industries, the medical sector is ramping up its AI adoption. This technology has shown significant potential in many use cases, particularly clinical trials, but some concerns remain. As more organizations use AI in medical research, more ethical questions emerge.
By Gunnar Esiason – I have cystic fibrosis (CF), a rare genetic condition that was historically known as a childhood disease. Today, CF is anything but that, and it’s due in large part to my community’s willingness to rally around clinical trial programs.
By Scott Gray – Patients suffering from chronic illness are often eager to participate in clinical trials with the hopes of finding a more effective treatment for themselves and others with their condition. This is especially true in the case of rare diseases, as these trials are often seen as a patient’s only opportunity for treatment.
By Ben van der Schaaf & Ben Enejo – Much has been written about the application of Artificial Intelligence and Machine Learning (AI/ML) in clinical development, and at first glance it is an obvious area of focus. Successful use of AI/ML capability requires vast amounts of data, and there have been….
By Hilary Marston MD MPH & Ann Meeker-O’Connell MS – Clinical trials play a crucial role in advancing science and supporting the development of new medical products to address unmet patient needs. Reliable data from well-designed trials about a medical product’s safety and effectiveness are critical.
By Liz Beatty – Tasked with reimagining patient-centric cancer clinical trials, the Bloomberg New Economy International Coalition has identified eliminating patient identification and enrollment barriers as top priorities.
By Robert E. Winkler MD – COVID-19 vaccines were developed extremely fast, approximately nine months from pandemic emergence to FDA approval in the U.S. This is, by a landslide, a record for one of the fastest development (and approval) of a vaccine, and significantly faster than traditional R&D timelines.